Condition (MeSH)
Facies
ClinicalTrials.gov lists 81 trials for Facies or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
81 of the 81 trials are tagged with Facies itself; the rest are tagged with a narrower condition beneath it.
When did Facies trials start? (22)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 9
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 7 |
| 2025 | 9 |
| 2024 | 4 |
| 2023 | 5 |
| 2022 | 3 |
| 2021 | 7 |
| 2020 | 4 |
| 2019 | 5 |
| 2018 | 2 |
| 2017 | 5 |
Showing 10 of 22 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 8 trials starting in 2026 and about 8 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Facies trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 6 |
| Phase 3 | 4 |
| Phase 4 | 9 |
| Not applicable | 42 |
| Observational | 15 |
How many Facies trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 3 |
| Recruiting | 13 |
| Active, not recruiting | 3 |
| Completed | 42 |
| Suspended | 1 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Facies trials? (7)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Pierre Fabre Dermo Cosmetique | 2 |
| Sofwave Medical LTD | 2 |
| Ulthera, Inc | 2 |
| Acorn Biolabs Inc. | 1 |
| Astellas Pharma Inc | 1 |
Showing 5 of 7 sponsors.
Interventions as named in the registry (15)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| HA Filler | 2 |
| Test Product | 2 |
| Comparator product | 1 |
| IM Oxytocin | 1 |
| Acupuncture | 1 |
Showing 5 of 15 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Facies trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Agitation | 1 | 1 |
| Appendicitis | 1 | 1 |
| Complex partial seizures | 1 | 1 |
| Complex regional Pain syndrome | 1 | 1 |
| Crohn's Disease | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Facies? (21)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Perceived functional impact of abnormal facial appearance. | Plastic and reconstructive surgery | 2003 | Yes |
| Facial symmetry after closed and open treatment of fractures of the mandibular condylar process. | Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons | 2000 | Yes |
| Botulinum toxin A treatment of overactive corrugator supercilii in thyroid eye disease. | The British journal of ophthalmology | 1998 | Yes |
| An evaluation of the impact of social interaction skills training for facially disfigured people. | British journal of plastic surgery | 1996 | Yes |
| A novel de novo intronic variant in ITPR1 causes Gillespie syndrome. | American journal of medical genetics. Part A | 2021 | No |
Showing 5 of 21 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.